West Pharmaceutical Services Inc (WST)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $29.01B
Last updated: Nov 17, 2026 at 4:20 PM ET
West Pharmaceutical Services Inc (WST) Statistics
West Pharmaceutical Services (WST) has a market cap of $29.01B and an enterprise value of $28.78B. Its return on invested capital of 16.85% compares with a 6.96% median across 11 similar companies.
Total Valuation
Enterprise value is 0.80% below the market cap, as cash exceeds debt.
| Market Cap | $29.01B |
|---|---|
| Enterprise Value | $28.78B |
| Latest price (Nov 17, 2026) | $414.27 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Nov 10, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Last Ex-Dividend Date | Nov 10, 2026 |
| Next Payment Date | Nov 18, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 8.8x and 9.8x. Its year-end P/E ranged from 27.5x to 59.6x from 2016 to 2025.
| P/E Ratio | 45.0x |
|---|---|
| Forward P/E | 43.3x |
| P/S Ratio | 8.8x |
| Forward P/S | 8.5x |
| P/B Ratio | 9.8x |
| P/TBV Ratio | 10.2x |
| P/FCF Ratio | 67.1x |
| P/OCF Ratio | 43.8x |
| PEG Ratio | 4.1 |
Enterprise Valuation
Counting debt and cash, the company is valued at 33.8x EBITDA and 66.6x free cash flow.
| EV / Earnings | 50.9x |
|---|---|
| EV / Sales | 8.6x |
| EV / EBITDA | 33.8x |
| EV / FCF | 66.6x |
Price Statistics
The stock is up 58.65% over 52 weeks and trades 8.21% above its 50-day average.
| Beta (1Y) | 0.62 |
|---|---|
| 52-Week Change | +58.65% |
| 1-Month Change | +8.04% |
| 3-Month Change | +17.57% |
| 6-Month Change | +36.39% |
| 5-Year Change | -4.02% |
| 10-Year Change | +442.71% |
| Total Return (1Y) | +59.01% |
| Total Return (3Y CAGR) | +6.72% |
| Total Return (5Y CAGR) | -1.41% |
| Return vs SPY (1Y) | +47.84% |
| Max Drawdown (1Y) | -18.76% |
| Max Drawdown (3Y) | -53.79% |
| Sharpe Ratio (1Y) | 1.51 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $382.84 |
| 200-Day Average | $322.83 |
| 52-Week Range | $223.37 to $437.99 |
| RSI (14 Days) | 63.0 |
| Average Volume (20 Days) | 771.34K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.82x current liabilities, and total debt is 0.07x shareholder equity.
| Current Ratio | 2.82x |
|---|---|
| Quick Ratio | 2.12x |
| Debt / Equity | 0.07x |
| Debt / EBITDA | 0.24x |
| Debt / FCF | 0.46x |
| Interest Coverage | 150.98x |
Returns and Efficiency
Return on invested capital is 16.85% over the last 12 months, against a 5-year average of 19.14%.
| Return on Equity (ROE) | 18.89% |
|---|---|
| Return on Assets (ROA) | 13.86% |
| Return on Invested Capital (ROIC) | 16.85% |
| ROE (5Y Average) | 20.93% |
| ROA (5Y Average) | 15.35% |
| ROIC (5Y Average) | 19.14% |
| Asset Turnover | 0.83x |
| Inventory Turnover | 4.67x |
| Receivables Turnover | 4.76x |
| Cash Conversion Cycle | 111 days |
Taxes
Income tax took 20.79% of pretax income over the last 12 months.
| Income Tax (TTM) | $144.20M |
|---|---|
| Effective Tax Rate | 20.79% |
Scores
WST has an Altman Z-Score of 19.50, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 19.50 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $3.33B over the last 12 months is up 12.38% from the 12 months before.
| Revenue | $3.33B |
|---|---|
| Revenue Growth (YoY) | +12.38% |
| Gross Profit | $1.22B |
| Operating Income | $680.40M |
| Pretax Income | $693.60M |
| Net Income | $564.90M |
| EBITDA | $860.80M |
| Reported EPS (TTM) | $9.20 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 73.28% of the $4.08B in total assets.
| Cash and Equivalents | $435.80M |
|---|---|
| Total Debt | $202.90M |
| Net Cash | $232.90M |
| Net Cash Per Share | $3.29 |
| Working Capital | $1.17B |
| Shareholder Equity | $2.99B |
| Book Value Per Share | $42.23 |
| Tangible Book Value | $2.88B |
| Tangible Book Per Share | $40.61 |
| Total Assets | $4.08B |
| Total Liabilities | $1.09B |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $225.30M of capital spending, operating cash flow left $436.90M of free cash flow.
| Operating Cash Flow | $662.20M |
|---|---|
| Capital Expenditures | $225.30M |
| Free Cash Flow | $436.90M |
| FCF Per Share | $6.21 |
| Depreciation and Amortization | $181.40M |
| Dividends Paid | $62.40M |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is 20.45%, against a 5-year average of 22.73%.
| Gross Margin | 36.79% |
|---|---|
| Operating Margin | 20.45% |
| Pretax Margin | 20.85% |
| Net Margin | 16.98% |
| EBITDA Margin | 25.87% |
| FCF Margin | 13.13% |
| Gross Margin (5Y Average) | 37.92% |
| Operating Margin (5Y Average) | 22.73% |
| Net Margin (5Y Average) | 19.37% |
Growth
Revenue grew 2.12% a year over 3 years, and EPS fell 5.25% a year.
| Revenue Growth (3Y CAGR) | +2.12% |
|---|---|
| Revenue Growth (5Y CAGR) | +7.44% |
| EPS Growth (3Y CAGR) | -5.25% |
| EPS Growth (5Y CAGR) | +8.94% |
| FCF Growth (3Y CAGR) | +2.19% |
| FCF Growth (5Y CAGR) | +9.48% |
| Operating Income Growth (3Y CAGR) | -7.29% |
| Book Value Per Share Growth (2Y CAGR) | +6.64% |
| Tangible Book Per Share Growth (2Y CAGR) | +6.97% |
Dividends and Yields
WST pays out 11.53% of earnings as dividends.
| Dividend Per Share (Annual) | $1.04 |
|---|---|
| Dividend Yield | 0.25% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +5.20% |
| Dividend Growth (5Y CAGR) | +5.51% |
| Payout Ratio | 11.53% |
| FCF Payout Ratio | 14.28% |
| Earnings Yield | 2.22% |
| FCF Yield | 1.49% |
| Buyback Yield | 1.52% |
| Shareholder Yield | 1.74% |
Stock Splits
The last split was a 2-for-1 forward split on Sep 27, 2013.
| Last Split Date | Sep 27, 2013 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 12 similar companies, WST has the 2nd highest P/E and the 3rd highest P/S.
P/E RatioPeer median 17.9x
P/S RatioPeer median 2.9x
ROICPeer median 6.96%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +9.01%
Dividend YieldPeer median 0.63%
| P/E Ratio | 45.0x vs 17.9x median |
|---|---|
| P/S Ratio | 8.8x vs 2.9x median |
| ROIC | 16.85% vs 6.96% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +12.38% vs +9.01% median |
| Dividend Yield | 0.25% vs 0.63% median |
Analyst Forecast
Consensus estimates put revenue growth at 8.56% and EPS growth at 19.40% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +8.56% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +19.40% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About WST
What is WST's market cap?
West Pharmaceutical Services has a market cap of $29.01B. Its enterprise value, which adds debt and subtracts cash, is $28.78B.
What is WST's P/E ratio?
West Pharmaceutical Services has a trailing P/E ratio of 45.0x and a forward P/E of 43.3x.
How many shares of WST are outstanding?
West Pharmaceutical Services has 70.80M shares outstanding. The count is down 1.94% from a year earlier.
Does WST pay a dividend?
Yes. West Pharmaceutical Services pays $1.04 a share a year, a dividend yield of 0.25%.
How much debt does WST have?
West Pharmaceutical Services has $202.90M of total debt and $435.80M of cash and equivalents, a net cash position of $232.90M.
WST pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors